ENVALITH
株式会社松屋アールアンドディ logo

Matsuya R&D Co., Ltd

7317Growth MarketTransportation Equipment

株式会社松屋アールアンドディ logo
Matsuya R&D Co., Ltd7317

Governance

The Board of Directors consists of 3 members (1 outside director, an outside ratio of approximately 33%), and the company has adopted the Audit & Supervisory Board structure. In addition to regular monthly Board meetings, a Management Committee and a Compliance Committee have been established, and internal control and compliance systems are in place.

Outside Director Ratio

33.3%

Nomination Committee

Not Established

Compensation Committee

Not Established

Risk Management

The Company has established the "Risk Management Regulations," under which each department and subsidiary manages risk under the officer in charge of risk management. Important matters, including sustainability risks, are discussed and reviewed quarterly by the Compliance Committee, with a system in place to report to the Board of Directors as necessary.

Shareholder Returns

Due to the planned tender offer by Omron Healthcare, delisting is expected, and no year-end dividend is planned for FY2026 (ending March 2026) (compared to ¥10 per share in the prior period). No dividend is planned for FY2027 (ending March 2027) either. No mention of share buybacks.

Dividend Policy

In light of the planned commencement of a tender offer by Omron Healthcare Co., Ltd. announced on December 15, 2025, no year-end dividend will be paid for FY2026 (ending March 2026) (no dividend). For FY2027 (ending March 2027) as well, no dividend is planned, as the company's shares are expected to be delisted through the tender offer and subsequent series of procedures. Note that a year-end dividend of ¥10 per share was already paid for FY2025 (ended March 2025) (total dividends of ¥213 million, payout ratio of 13.6%).

Dividend

None

Share Buyback

None

Shareholder Benefits

None

ESG

Promoting ESG management under the corporate philosophy of "Contributing to humanity by advancing science and technology through Safety & Medical Healthcare." CO2 emissions reduction is treated as a priority issue, with total Scope 1+2 emissions reduced from 3,502.74tCO2 in FY2024 (ended March 2024) to 2,082.34tCO2 in FY2026 (ending March 2026). The company is working to reduce emissions through measures such as utilizing renewable energy at its Vietnam site, which accounts for over 90% of electricity consumption.

Last updated: June 26, 2026